Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026EP EuropaceOpen Access

Catheter ablation for sustained VT in HCM shows a ~44% recurrence rate.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does catheter ablation provide long-term arrhythmia control in patients with hypertrophic cardiomyopathy and sustained ventricular tachycardia?

Population

16 patients with hypertrophic cardiomyopathy who underwent catheter ablation for sustained ventricular…

Design

Cohort

Follow-up

mean 49.6 ± 32.9 months (median 53.4, IQR 18.3–84.6)

Key result

Catheter ablation for sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy resulted in a 43.8% VT recurrence rate and a median VT-free survival of 73.5 months.

Authors

AKA KeresteciCCC CoteliHYH Yorgun

Discussion

Loading...

Member takes

Overview

May support durable VT control in select cases; hypothesis-generating and should not yet change practice.

Key Points

  • Evaluate the clinical characteristics and long-term outcomes of catheter ablation for sustained ventricular tachycardia in hypertrophic cardiomyopathy.
  • Retrospective single-center study of 16 patients with hypertrophic cardiomyopathy who underwent catheter ablation.
  • Data on clinical, echocardiographic, and procedural outcomes were collected from electronic medical records.
  • Mean follow-up duration of 49.6 ± 32.9 months to assess long-term outcomes.
  • 43.8% of patients experienced VT recurrence during follow-up.
  • Median VT-free survival time was 73.5 months (95% CI 33.9–113.0).
  • No major procedural complications were observed.

Study Design

Type

Observational (n=16)

Multicenter

No

Structured PICO

Does catheter ablation provide long-term arrhythmia control in patients with hypertrophic cardiomyopathy and sustained ventricular tachycardia?

P
Population
16 patients with hypertrophic cardiomyopathy who underwent catheter ablation for sustained ventricular tachycardia, followed for a mean of 49.6 months.
E
Exposure
Catheter ablation for sustained ventricular tachycardia (combined endocardial and epicardial mapping/ablation in 56%, endocardial-only ablation in 44%)
O
Outcome
Ventricular tachycardia (VT) recurrence and VT-free survival timehard clinical

Catheter ablation for sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy is feasible, safe, and provides acceptable long-term arrhythmia control with a median VT-free survival of 73.5 months.

Cite This Study

Keresteci et al. (2026) conducted an observational in Hypertrophic cardiomyopathy with sustained ventricular tachycardia (n=16). Catheter ablation was evaluated on Ventricular tachycardia recurrence. Catheter ablation for sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy resulted in a 43.8% VT recurrence rate and a median VT-free survival of 73.5 months.

synapsesocial.com/papers/6a3f97bb125782b61d865978https://doi.org/10.1093/europace/euag105.1101
View Full Paper
Ask AI
Bookmark
Share